Correct

Bryan Johnson launches a Netflix documentary - Yes

Public supplement companies up in price - Yes, Herbalife ($HLF) and Jamieson Wellness ($JWLLF); up 39% and 17%

New enzyme-based biomarker monitoring - Yes, Nanozyme-based wearable biosensors for application in healthcare; Electrochemical Microneedles for Real-Time Monitoring in Interstitial Fluid: Emerging Technologies and Future Directions

QuantifiedSelfDAO creates a decentralized clinical trial to aggregate health, biomarker, genetic and supplement data to understand health - Yes, BiohackerDAO is doing this

Academic backlash to biohackers - Yes, particularly around privacy and bodily autonomy

ChatGPT conducts therapy at scale - Yes, especially with GenZ

New sleep molecules are engineered - Yes, many companies building here

Diabetes cell therapy continues to move through the clinic - Yes, Sana particularly is promising as their cell therapy doesn’t require immunosuppression; Vertex also shows positive data for Zimislecel but treatment requires immunosuppression

China pours funding into AI-bio research - Yes, state-led investment is giving billions to tech with biomedicine being a core theme

5% of monogenic diseases have gene therapy drugs in the clinic - Yes, 35% (3900) are in clinical trials (mostly) or approved. This was more of an initial mis-calculation on my end vs. true progress of biotech in 2025.

Not yet

Apple goes to 4.5T market cap (in part due to health tracking) - No $3.14T

Bryan Johnson Blueprint products in high-end grocers - No

New verbiage for food which has no pesticides, no microplastics “hyper-ganic” - No

Countries with one healthcare system have more of a biohacking movement - No

Many new biohacking companies - Hard to quantify but yes

Deepmind releases an enzyme specific model - No, but Baker lab made breakthroughs with generating new enzymes with complex active sites; AI.zymes combining evolutionary enzyme design tools (e.g. RosettaDesign, ProteinMPNN, ESMFold) under one framework; ProCALM conditional-generation model based on adapters on ProGen2, targeting enzyme family/function conditioning; Unizyme predicts proteolytic cleavage sites using active-site-informed architecture